Orbis Biosciences® announces New Management Hires with addition of Chief Licensing Officer and Vice President of Business Development

orbis biosciences announces new management hires with addition of chief licensing officer and vice president of business development

KANSAS CITY, Mo., June 19, 2018 /PRNewswire/ — Orbis Biosciences is pleased to announce and welcome Karl Strohmeier as Chief Licensing Officer and Brad Spitz as Vice President of Business Development.  These two associates bring over five decades of experience in the pharmaceutical industry.  Karl will be responsible for the identification and development of strategic relationships, alliance management, contract negotiations and other strategic initiatives impacting Orbis, and Brad will lead the business development on a global basis.

Karl has over 30 years of pharmaceutical industry experience in business development, global commercial development, strategic planning, finance and general management.  With an MBA from the University of Chicago and a BS in Pharmacy from the University of Illinois, Karl began his career at Marion Laboratories and has worked for Marion Merrell Dow, Hoerchst Marion Roussel, Teva Marion Partners, CyDex, Pharmion and most recently Teva Pharmaceuticals.  He is a certified Licensing Professional (CLP) and member of the Licensing Executive Society.  www.linkedin.com/in/karl-strohmeier-8367745

Brad is a highly accomplished professional in the medical sales industry with over 25 years of experience. Brad completed a BS degree with a double major in Economics and Communication Arts at the University of Wisconsin- Madison and an MBA at Elon University in North Carolina.  The first 20 years of his career were spent at Johnson & Johnson Medical in various sales and management capacities within the surgical, capital equipment, and oncology diagnostics markets.  Most recently Brad was the US Vice President of Sales for ANGLE North America leading the launch of a novel oncology diagnostic platform for circulating tumor cells. www.linkedin.com/in/brad-spitz-517362

Karl and Brad’s proven experience in facilitating long term business relationships with both customers and industry partners enhance Orbis Biosciences’ ability to meet the needs of our customers as we continue to provide quality and innovative technology to the marketplace.

About Orbis Biosciences – Orbis is a pharmaceutical manufacturing technology company focused on licensing its technology to pharmaceutical companies to optimize their product portfolios. Orbis develops customized formulations and intellectual property for pharmaceutical product manufacture, leveraging Orbis’ novel technology platforms: Optimμm® precision encapsulation for oral delivery, StratμmTM precision encapsulation for injectable delivery, and the Unisun® platform for enabling sustained-release otic therapies.  Providing industry innovation, the company offers cost-effective reformulation pathways to improve pharmaceutical products for improved health outcomes. 

For more information about Orbis, visit www.orbisbio.com  or contact us at info@orbisbio.com

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/orbis-biosciences-announces-new-management-hires-with-addition-of-chief-licensing-officer-and-vice-president-of-business-development-300668213.html

SOURCE Orbis Biosciences

Related Links


Read on The Source

Author: HEDGE

Hedge Accordingly was founded ahead of the global financial crisis in January of 2008, with the goal of providing our readers our unique take on latest news on stocks, wall street, volatility, news on wall street, articles on investing, trading, options, stocks, futures, #cnbc, #crudeoil, Bitcoin. Hedge Accordingly produces both original, and aggregated Wallst news content from top publishers around the world. We curate aggregated content covering the latest news on politics, stocks, wall street, and the tech industry. We also provide free stock charting, quotes and a bitcoin, forex and currency exchange. Learn More About HEDGEaccordingly.com